首页> 外文OA文献 >Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab

【2h】

Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab

机译：VEGF基因多态性对接受一线治疗（包括氟尿嘧啶，伊立替康和贝伐单抗）的转移性结直肠癌患者的预测价值

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The aim of this study is to evaluate the influence of germline vascular endothelial growth factor (VEGF) gene polymorphisms (VGPs) on the efficacy of the anti-VEGF antibody bevacizumab (Bev) in metastatic colorectal cancer (MCRC) patients.

机译：本研究的目的是评估种系血管内皮生长因子（VEGF）基因多态性（VGP）对抗VEGF抗体贝伐单抗（Bev）在转移性结直肠癌（MCRC）患者中的疗效的影响。

著录项

作者
Formica V; Palmirotta R; Del Monte G; Savonarola A; Ludovici G; De Marchis ML; Grenga I; Schirru M; Guadagni F; Roselli M;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. [J] . Formica V, Palmirotta R, Del Monte G, International journal of colorectal disease. . 2011,第2期

机译：VEGF基因多态性对接受一线治疗（包括氟尿嘧啶，伊立替康和贝伐单抗）的转移性结直肠癌患者的预测价值。
2. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab [J] . Vincenzo Formica, Raffaele Palmirotta, Girolamo Del Monte, International Journal of Colorectal Disease . 2011,第2期

机译：VEGF基因多态性对接受一线治疗（包括氟尿嘧啶，伊立替康和贝伐单抗）的转移性结直肠癌患者的预测价值
3. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable|[sol]|metastatic colorectal cancer (mCRC) [J] . J Souglakos, N Ziras, S Kakolyris, British Journal of Cancer . 2012,第3期

机译：CAPIRI（卡培他滨，伊立替康）加贝伐单抗与FOLFIRI（亚叶酸，5-氟尿嘧啶，伊立替康）加贝伐单抗的II期随机试验作为一线治疗不可切除的结肠癌（mCRC）患者
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Randomised phase-II trial of CAPIRI (capecitabine irinotecan) plus bevacizumab vs FOLFIRI (folinic acid 5-fluorouracil irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) [O] . J Souglakos, N Ziras, S Kakolyris, 2012

机译：CAPIRI（卡培他滨伊立替康）加贝伐单抗与FOLFIRI（亚叶酸5-氟尿嘧啶伊立替康）加贝伐单抗的II期随机试验作为不可切除/转移性结直肠癌（mCRC）患者的一线治疗
7. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab [O] . Vincenzo Formica, Raffaele Palmirotta, G. Del Monte, 2011

机译：VEGF基因多态性对接受一线治疗（包括氟尿嘧啶，伊立替康和贝伐单抗）的转移性结直肠癌患者的预测价值

Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab

摘要

著录项

相似文献

相关主题

期刊订阅